GLP-1 Drugs and Alcohol Cravings: What New Research Shows in 2026
GLP-1 drug semaglutide may help heavy drinkers cut alcohol intake, reduce cravings, and offer a promising new addiction treatment.
What Happens After Stopping GLP-1 Drugs? Weight Regain and New Research
Quitting GLP-1 drugs or a diet can cause weight regain—two strategies could help prevent Millions of Americans are now using GLP-Drugs such as Wegovy and Zepbound to lose weight and improve their health. These medicines can produce significant weight loss. But an important question remains: What happens when treatment stops? Research shows that weight regain … Read more
Obesity Drugs in 2026: Why the Focus Is Shifting to Long-Term Weight Management
Weight Loss Drug Market Could Reach $150 Billion Globally | Morgan Stanley The race to develop obesity drugs is entering a new phase. For several years, the biggest question was simple: How much weight can a drug help people lose? Now the focus is changing. Doctors and researchers are increasingly asking whether patients can maintain … Read more
GLP-1 Weight Loss and Muscle Loss: What Patients Should Know in 2026
How weight loss drugs may trigger severe muscle loss | – The Times of India GLP-1 and related weight-loss medicines have changed the treatment of obesity. Medicines such as semaglutide and tirzepatide can help many people lose substantial amounts of weight and improve important health measures. But weight loss is not made up of body … Read more
New Weight-Loss Drug May Burn Fat Without Muscle Loss: What 2026 Research Shows
Research for ‘New weight-loss drug without muscle loss’ is increasingly focused on reducing body fat while preserving muscle. Losing weight is not always the same as losing body fat. Some people taking modern weight-loss medicines can lose lean mass along with fat. That has increased interest in treatments that could target body fat while doing … Read more
Who Benefits Most From Weight-Loss Drugs Like Wegovy and Mounjaro?
New study reveals lifelong use of weight-loss drugs like Mounjaro and Wegovy may be necessary A New Study Offers Clues About Why GLP-1 Weight Loss Varies Wegovy and Mounjaro have changed the way doctors approach obesity treatment. Yet one question remains common: why do some people lose much more weight than others on these medications? … Read more
Retatrutide for Weight Loss: What 2026 Research Shows About the Next-Generation Drug
Eli Lilly’s Retatrutide Hits Record Weight Loss, Challenges Surgery Efficacy | Whalesbook Retatrutide Is Producing Remarkable Weight-Loss Results The next generation of obesity medicines is moving quickly. One of the most closely watched candidates is retatrutide for weight loss, an experimental drug being developed by Eli Lilly. In May 2026, Lilly reported Phase 3 TRIUMPH-1 … Read more
Wegovy HD 7.2 mg: What the FDA Approval Means for Weight Loss Treatment
FDA Approves New High-Dose of Wegovy HD 7.2 mg On March 19, 2026, the U.S. Food and Drug Administration approved Wegovy HD, a 7.2 mg once-weekly injectable dose of semaglutide, for certain adults with obesity or overweight plus at least one weight-related condition. The higher dose gives eligible patients another treatment option when clinically appropriate. … Read more
Foundayo (Orforglipron) for Weight Loss: 7 Facts About the New GLP-1 Pill
Foundayo(orforglipron) has moved from the clinical-trial stage into real-world U.S. obesity treatment. On April 1, 2026, the U.S. Food and Drug Administration approved Foundayo (orforglipron), an oral GLP-1 receptor agonist developed by Eli Lilly. It is approved for adults with obesity, or adults who are overweight and have at least one weight-related medical condition, when … Read more